TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04273763
Drug: Recombinant Human Interferon α2b Spray
Normalized name: Interferon alfa-2b, recombinant
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
Study: NCT00935246
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Study: NCT01433380
Drug: PF-05175157
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Study: NCT04335305
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
Study: NCT02237534
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02237534
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02319629
Drug: URSODIOL
Normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
Study: NCT04297280
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PD-1 immune check inhibitor
Study: NCT00552422
Drug: domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg orally four times per day
Study: NCT03602976
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight-based dosing
Study: NCT03378310
Drug: BMS-986205 reference tablet
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single, 100 mg oral dose.
Study: NCT03378310
Drug: BMS-986205 tablet with free base
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single, 100 mg oral dose.
Study: NCT02600780
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparison of two anti-hyperuricemic molecules
Study: NCT02600780
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two anti-hyperuricemic molecules
Study: NCT02401425
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02401425
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04612465
Drug: Fibringlue
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
Study: NCT02294565
Drug: VST-1001
Normalized name: VST
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
Study: NCT02294565
Drug: 99mTc-labeled sulfur colloid
Normalized name: technetium (99mTc) sulfur colloid
DrugBank: Technetium Tc-99m sulfur colloid (DB09397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
Study: NCT01510769
Drug: Lesinurad
Normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, 400 mg once daily (QD)
Study: NCT01510769
Drug: Lesinurad
Normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, 200 mg QD
Study: NCT01510769
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80 mg
Study: NCT02674204
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
Study: NCT00437008
Drug: Benfotiamine 1050mg, 3 days
DrugBank: Benfotiamine (DB11748)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269540
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selective serotonin reuptake inhibitor
Study: NCT02269540
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selective serotonin reuptake inhibitor
Study: NCT02269540
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: natural health product
Study: NCT04040322
Drug: Iloprost Injection, for intravenous use
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study: NCT02747472
Drug: GIP-A
Normalized name: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GIP receptor antagonist
Study: NCT00512629
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven is a fish based intravenous fat emulsion
Study: NCT00512629
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid is a plant based intravenous fat emulsion
Study: NCT03929094
Drug: Paclitaxel for Injection（Albumin Bound）
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT03929094
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT02886494
Drug: Matched vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
Study: NCT02277548
Drug: Lyrica 300 mg
Normalized name: Lyrica 300 MG Oral Capsule
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lyrica 300 mg per day
Study: NCT02067975
Drug: Tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03370705
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 250 ULS twice daily per oral route
Study: NCT02172534
Drug: Tiotropium bromide low
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02172534
Drug: Tiotropium bromide medium
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02172534
Drug: Tiotropium bromide high
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00166556
Drug: Campath-1H and Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02956590
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin
Study: NCT00486811
Drug: Tapentadol ER (100 to 250 mg twice daily)
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study: NCT00486811
Drug: Oxycodone CR (20 to 50 mg twice daily)
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study: NCT00926315
Drug: calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
Study: NCT00926315
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcitriol 0.25 mcg PO bid
Study: NCT01742390
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
Study: NCT01742390
Drug: risperidone or paliperidone
Normalized name: Paliperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00266058
Drug: Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
Study: NCT04270279
Drug: Nitroglycerin tablets
Normalized name: nitroglycerin Sublingual Tablet
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Be used when angina attack
Study: NCT00834080
Drug: Medisorb naltrexone 380 mg
Normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
Study: NCT03396952
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00027872
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01986556
Drug: Lesinurad 400 mg (Site 1)
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01986556
Drug: Lesinurad 400 mg (Site 2, Lot A)
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01986556
Drug: Lesinurad 400 mg (Site 2, Lot B)
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03366272
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
Study: NCT00185198
Drug: Testogel (Testosterone, BAYV001915)
Normalized name: Testopel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
Study: NCT03366272
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: eight cycles of R-GemOx in 2-wk intervals
Study: NCT03366272
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: eight cycles of (R)-GemOx in 2-wk intervals
Study: NCT00256217
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg. oral every day for 2 - 4 weeks
Study: NCT00761644
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
Study: NCT00761644
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
Study: NCT00761644
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
Study: NCT04120311
Drug: Episcleral Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained Release Episcleral Dexamethasone
Study: NCT01054547
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
Study: NCT01054547
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
Study: NCT00795587
Drug: variation of mannitol dose
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
Study: NCT01554917
Drug: Iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: taken orally, 2 tablets/day (bid)
Study: NCT04017845
Drug: Tribenoside 400 mg + lidocaine 40 mg suppositories
Normalized name: lidocaine / tribenoside
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
Study: NCT04017845
Drug: Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
Study: NCT04548869
Drug: CDX-0159
Normalized name: Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide wi
DrugBank: Barzolvolimab (DB18934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03449524
Drug: 75mg CXA-10
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study: NCT03449524
Drug: 150mg CXA-10
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study: NCT02929498
Drug: GSK2879552
Normalized name: GSK2879552
DrugBank: GSK-2879552 (DB16895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2879552 will be administered orally as continuous daily dosing.
Study: NCT02929498
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
Study: NCT02230332
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04051840
Drug: ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
Normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
Study: NCT02559492
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Study: NCT02559492
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat tablets will be administered orally, twice daily.
Study: NCT02559492
Drug: INCB050465
Normalized name: INCB050465
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB050465 tablets will be administered orally once daily.
Study: NCT00167492
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 720 mg by mouth every 12 hours
Study: NCT01873131
Drug: topical timolol maleate
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
Study: NCT00001972
Drug: 15 O Water
Normalized name: water, O-15
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01295879
Drug: Ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU's orally per week, for 8 weeks
Study: NCT04075292
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acalabrutinib 100 mg twice daily orally
Study: NCT04075292
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
Study: NCT04075292
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
Study: NCT02086968
Drug: Injectafer
Normalized name: Injectafer
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
Study: NCT02086968
Drug: Ferrous Sulfate tablets
Normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325mg (1 tablet) three times a day for 28 days
Study: NCT00210925
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04530422
Drug: Sofosbuvir plus Ledipasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
Study: NCT01556646
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 to 30mg qd titrated to sodium concentration
Study: NCT02032043
Drug: Annual versus Semiannual Albendazole plus Ivermectin MDA
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
Study: NCT00627575
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
Study: NCT00627575
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin will available as 40 mg tablets.
Study: NCT03444480
Drug: Remimazolam Tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose plus supplemental doses
Study: NCT00995566
Drug: Sitaxentan sodium
Normalized name: Sitaxentan sodium
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.